Danicopan Terminated Phase 2 Trials for C3 Glomerulonephritis / IC-MPGN / Immune Complex Membranoproliferative Glomerulonephritis / Complement 3 Glomerulopathy (C3G) / Membranoproliferative Glomerulonephritis, Type II Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Terminated | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT03459443 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 |